HighVista Strategies’s Janux Therapeutics JANX Stock Holding History

HighVista Strategies’s Portfolio JANX Stock Details JANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$743K	Sell	48,376 -1,007	-2%	-$14.6K	0.17%	133
2026 Q1	$686K	Buy	49,383 +7,940	+19%	+$109K	0.19%	137
2025 Q4	$572K	Sell	41,443 -13,807	-25%	-$325K	0.15%	139
2025 Q3	$1.35M	Sell	55,250 -7,186	-12%	-$175K	0.33%	97
2025 Q2	$1.44M	Sell	62,436 -12,120	-16%	-$319K	0.53%	69
2025 Q1	$2.01M	Buy	74,556 +4,841	+7%	+$182K	0.78%	37
2024 Q4	$3.73M	Buy	69,715 +46,243	+197%	+$2.45M	1.39%	9
2024 Q3	$1.07M	Buy	23,472 +140	+0.6%	+$6.09K	0.37%	100
2024 Q2	$977K	Buy	+23,332	New	+$1.1M	0.36%	102

Other funds holding JANX

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

HighVista Strategies's JANX Position: Q2 2026 in Review

HighVista Strategies reduced its Janux Therapeutics (JANX) stake by 2% in Q2 2026, selling an estimated $14.6K and leaving 48,376 shares worth $743K. The position accounts for 0.17% of the portfolio, ranked #133.

HighVista Strategies first reported a position in JANX in Q2 2024 and has held it in 9 quarters since. The position peaked at $3.73M in Q4 2024. 198 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

HighVista Strategies held 48,376 shares of Janux Therapeutics worth $743K as of Q2 2026.
HighVista Strategies sold 1,007 Janux Therapeutics shares in Q2 2026, an estimated $14.6K.
Janux Therapeutics made up 0.17% of HighVista Strategies's portfolio in Q2 2026, its #133 holding.
HighVista Strategies first reported a position in Janux Therapeutics in Q2 2024 and has held it in 9 quarters since.
HighVista Strategies's Janux Therapeutics position peaked at $3.73M in Q4 2024.
198 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on HighVista Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.